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ABSTRACT
Objectives To study the effect of insulin treatment in
combination with metformin or an insulin secretagogue,
repaglinide, on glycaemic regulation in non-obese
patients with type 2 diabetes.
Design Randomised, double blind, double dummy,
parallel trial.
Setting Secondary care in Denmark between 2003 and
2006.
Participants Non-obese patients (BMI ≤27) with
preserved beta cell function.
Interventions After a four month run-in period with
repaglinide plus metformin combination therapy,
patients with a glycated haemoglobin (HbA1c)
concentration of 6.5% or more were randomised to
repaglinide 6 mg or metformin 2000 mg. All patients also
received biphasic insulin aspart 70/30 (30% soluble
insulin aspart and 70% intermediate acting insulin
aspart) 6 units once a day before dinner for 12 months.
Insulin dose was adjusted aiming for a fasting plasma
glucose concentration of 4.0-6.0 mmol/l. The target of
HbA1c concentration was less than 6.5%. Treatment was
intensified to two or three insulin injections a day if
glycaemic targets were not reached.
Main outcome measure HbA1c concentration.
Results Of the 459 patients who were eligible, 102 were
randomised,and97completedthetrial.Patientshadhad
type 2 diabetes for approximately 10 years. At the end of
treatment, HbA1c concentration was reduced by a similar
amount in the two treatment groups (insulin plus
metformin: mean (standard deviation) HbA1c 8.15%
(1.32) v 6.72% (0.66); insulin plus repaglinide: 8.07%
(1.49) v 6.90% (0.68); P=0.177). Total daily insulin dose
and risk of hypoglycaemia were also similar in the two
treatment groups. Weight gain was less with metformin
plus biphasic insulin aspart 70/30 than with repaglinide
plus biphasic insulin aspart 70/30 (difference in mean
body weight between treatments −2.51 kg, 95%
confidence interval −4.07 to −0.95).
Conclusions In non-obese patients with type 2 diabetes
and poor glycaemic regulation on oral hypoglycaemic
agents, overall glycaemic regulation with insulin in
combination with metformin was equivalent to that with
insulin plus repaglinide. Weight gain seemed less with
insulin plus metformin than withinsulin plus repaglinide.
Trial registration NCT00118963
INTRODUCTION
Inpatientswithtype2diabetes,metforminandinsulin
secretagogues (for example, sulphonylureas), alone or
in combination with insulin, are among the most
widely used oral hypoglycaemic agents.
Metformin is an oral hypoglycaemic agent that tar-
getsinsulinresistance.IntheUKProspectiveDiabetes
Study(UKPDS),metformintreatmentreducedtherisk
of cardiovascular disease in obese patients with type 2
diabetes,
12afindingrecentlyreinforcedbyastudyina
differentsetting.
3Thus,metforministhepreferredglu-
cose lowering drug to use as monotherapy or in com-
bination with insulin in obese patients with type 2
diabetes.
124-7
“Insulin providing” agents such as insulin secreta-
goguesorinsulinareconsideredtheprimarytreatment
fornon-obesepatientswithtype2diabetes,
145because
this group usually has more pronounced insulin secre-
tion deficiencies and less insulin resistance than obese
patients.
8 In the recent 10 year follow-up of the
UKPDS, however, treatment with insulin secreta-
gogues or insulin reduced cardiovascular events and
mortality in a combined group of non-obese and
obese patients with type 2 diabetes.
2
Many patients with type 2 diabetes eventually
experience glycaemic failure on oral hypoglycaemic
agents, even in combination therapy, and need addi-
tional insulin treatment.
9-13 Observational
1415 and
randomised
16 studies in non-obese patients with type
2 diabetes have indicated that the glucose lowering
effect of metformin is equal to that of insulin secreta-
gogues as monotherapy. However, it is not known
whether insulin plus metformin has a similar glucose
loweringpotencyinnon-obesepatientswithtype2dia-
betes as an “insulin providing” combination regimen
of insulin plus an insulin secretagogue. Despite this
unsolved question, international consensus statements
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combinationwithinsulinsecretagoguesorinsulininall
patients with type 2 diabetes, regardless of BMI.
7
Repaglinideisameglitinideanalogue:a shortacting
insulin secretagogue with a similar glucose lowering
effect, lower risk of hypoglycaemia, and better effect
on cardiovascular disease surrogate markers than
other insulin secretagogues such as glibenclamide.
17-20
An observational study of cardiovascular events in
patientswithtype2diabetessuggestedthatrepaglinide
has similar cardioprotective effects to metformin,
whereas most sulphonylureas would be less effective
thanmetformin.
21Henceforlongtermuseorasamet-
formin comparator in clinical trials, repaglinide could
be considered the insulin secretagogue of choice,
despite being more expensive than sulphonylureas.
Several insulin treatment regimens are available for
patients with type 2 diabetes. Biphasic insulin aspart
70/30 is a premixed insulin analogue that comprises
30% soluble insulin aspart and 70% intermediate act-
ing insulin aspart. Premixed insulin analogues, includ-
ing biphasic insulin aspart 70/30, have advantages
compared with other insulin regimens such as the
widely used basal insulin regimen (that is, a once
daily intermediate acting insulin). Such advantages
includelowerglycatedhaemoglobin(HbA1c),lesspro-
nouncedfluctuationsin bloodglucoseaftermeals and,
in some studies, lower risk of hypoglycaemia.
22-29
Moreover, studies in various ethnic populations have
indicated that biphasic insulin aspart 70/30 is safe and
effective with up to three injections a day.
30-32 Such
therapy could be more convenient than the basal
bolus regimen (four daily injections) in patients who
need multiple daily injections.
33
Inthistrialweaimedtotestthehypothesisthatcom-
bination therapy for one year with metformin plus
biphasic insulin aspart 70/30 has equal glucose lower-
ingefficacytotheinsulinsecretagoguerepaglinideplus
biphasic insulin aspart 70/30 in non-obese patients
with type 2 diabetes who have poor glycaemic control
oncombinationtherapyoforalhypoglycaemicagents.
METHODS
The study was an investigator initiated, single centre,
prospective, randomised, double blind, double
dummy, parallel trial of metformin plus biphasic insu-
linaspart70/30comparedwithrepaglinideplusbipha-
sic insulin aspart 70/30 (hereafter termed “insulin” in
the Methods and Results sections).
Patients were enrolled between February 2003 and
September 2004 at Steno Diabetes Center, Gentofte,
Denmark. A targeted approach using electronic
patient records as search objects for eligibility was
used among approximately 5500 patients, about 40%
of whom had type 2 diabetes. All potentially eligible
non-obese patients with type 2 diabetes identified
wereinvitedtoparticipate(fig1).Atotalof155patients
accepted and attended a screening visit. Of these, 53
patients declined to participate before randomisation.
Information on patients’ reasons for refusing to parti-
cipate was not collected. Patients gave written
informed consent at the screening visit.
Atotalof459patientswereeligibleforinclusionand
were approached by trial clinicians to join the study,
and 155 consented and entered the screening phase.
A total of 133 patients with a BMI of 27 or less (corre-
sponding to the criterion for non-obesity criteria used
in the UKPDS) and an initial HbA1c concentration of
6.5% or more were selected for inclusion (box 1).
After the screening period, patients entered a four
month run-in period. All patients received combina-
tion therapy with metformin (1000 mg twice a day)
plus repaglinide (2 mg three times a day) and stopped
prior glucose lowering treatments. Doses were
adjusted by forced titration to reach maximum toler-
ated doses (see web appendix 1).
Initiated repaglinide plus insulin (n=49) Initiated metformin plus insulin (n=52)
Completed repaglinide plus insulin (n=46) Completed metformin plus insulin (n=51)
Eligible and approached (n=459)
Screened (n=155)
Completed trial (n=97)
Initiated metformin plus repaglinide (n=133)
Completed metformin plus repaglinide (n=119)
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Declined (n=304)
Declined after screening (n=22):
  Not eligible (n=20)
  Lost to follow-up (n=1)
  Not compliant (n=1)
Excluded during metformin plus
  insulin (n=1):
    Personal reason (n=1)
Excluded during repaglinide plus
  insulin (n=3):
    Study drug intolerance (n=1)
    Hypoglycaemia (n=1)
    Lost to follow-up (n=1)
Excluded during run-in (n=14):
  Poor glycaemic regulation (n=6)
  Gastrointestinal symptoms (n=1)
  Poor glycaemic regulation and
    gastrointestinal symptoms (n=1)
  Fatal myocardial infarction (n=1)
  Stroke (n=1)
  Cancer of the colon (n=1)
  Pneumonia (n=1)
  Personal reasons (n=1)
  Lost to follow-up (n=1)
Excluded after run-in (n=17):
  HbA1c <6.5% (n=7)
  BMI >27 (n=2)
  HbA1c <6.5% and BMI >27 (n=2)
  Refused to start insulin (n=2)
  Relative contraindication to insulin (n=1)
  Personal reasons (n=3)
Fig 1 | Patient flow scheme.
aOne patient (randomised to insulin plus repaglinide) who did not
start the study medication was excluded from all statistical analyses; therefore, 101 patients
were included in the analysis
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randomlyallocated to receive 12 monthscombination
therapy with either repaglinide, insulin, and placebo
metformin,ormetformin,insulin,andplaceborepagli-
nide. Active and placebo tablets were identical in
appearance, taste, and smell. The maximum dose of
repaglinide was 2 mg three times a day (total daily
dose: 6 mg) and metformin 1000 mg twice a day
(total daily dose: 2000 mg). The near maximum
doses of metformin and repaglinide were chosen on
the basis of previous dose-response studies, which
showed only slight additional glucose lowering effect
and more side effects with higher doses of both
drugs.
36-38 Patients were advised to take tablets just
before or during meals.
The starting dose of insulin was six units injected
before dinner. Patients self adjusted insulin dose
every third day according to a predefined algorithm,
aiming for a fasting plasma glucose concentration of
4.0-6.0 mmol/l (see web table A). The target HbA1c
concentration was less than 6.5%. If glycaemic targets
were not reached, patients intensified to two or three
insulin injections a day at three, six, or nine months
using prespecified criteria (see web appendix 1).
Doses were reduced if adverse events with possible
relation to either of the study medications occurred.
Once adverse events had resolved, drug dose was
increased again; if adverse events recurred, the lower
dose was continued.
Accordingtolocalguidelines,patientswhowerenot
receiving concomitant treatment with aspirin or a sta-
tin initiated such treatments (see web appendix 1).
Otherwise, non-vital changes in non-study medica-
tions were postponed until after the trial. Patients
wereaskednottomakeanylifestylemodificationsdur-
ing the trial.
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the
Ethics Committee of Copenhagen County, Denmark.
Outcome measures
The primary outcome was HbA1c concentration (nor-
mal limits: 4.1-6.4%). Secondary outcomes were insu-
lin doses, self monitored plasma glucose, measures of
adiposity, and adverse events. Outcomes were
assessed at enrolment (screening period: −4.5 and −
4 months visits), at baseline (0 month visit), and on
the last day of treatment (12 month visit). Clinical sta-
tus was assessed at −2, 3, 6, and 9 months. Follow-up
ended in February 2006.
HbA1c concentration was measured by ion
exchange high performance liquid chromatography
(Tosoh Automated Glycohemoglobin Analyser
HLC-723 G7, Tosoh Bioscience, Minato, Japan),
aligned to the Diabetes Control and Complication
Trial standard. HbA1c concentration was measured in
duplicate (each in a separately drawn sample) at all
study visits. Blood sampling procedures as well as
methodstoassessthesecondaryoutcomesandcompli-
ance are described elsewhere (see web appendix 1).
Statistics
Random allocation was centrally performed in blocks
ofthreeandfour,stratifiedbybaselinelevelsofHbA1c
and BMI (see web appendix 1). The 101 randomised
patients were evaluated for screening, outcome, and
safety variables, as well as for compliance and report-
ing of adverse events. For the primary outcome, the
randomised population was analysed on an intention
to treat basis, with last observation carried forward for
missing values at the end of treatment. For HbA1c, the
last observation was carried forward only if both mea-
surements were missing at the end of treatment. Only
values obtained a minimum of three months after ran-
domisation were used for last observation carried for-
ward (one patient). Insulin dose was analysed in a
similarwaytotheprimaryoutcome,whereasothersec-
ondary outcomes were analysed without last observa-
tion carried forward(owingto non-fastingassessments
at intermediate study visits; for example, measures of
adiposity). The statistical tests of efficacy included
measurements taken before randomisation, represent-
ing baseline (0 month); and after 12 months or last
observation carried forward, representing the end of
treatment. Hence, measurements obtained at inter-
mediatestudyvisitswereincludedinthestatisticalana-
lyses, except for measurements used for last
observation carried forward. Differences in treatment
efficacy between the randomised interventions were
evaluatedbycomparisonofendoftreatmentmeasure-
ments with those taken at the baseline (“change from
baseline”). The analysis of self monitored plasma glu-
cose measurements included those measurements
Box 1: Inclusion, exclusion, and withdrawal criteria
Inclusion criteria
 Type 2 diabetes mellitus, defined as age at onset of diabetes ≥40 years; fasting serum
Cp e p t i d e≥300 pmol/l or a non-fasting or glugacon stimulated serum C peptide ≥600
pmol/l (measured either during the screening or run-in period); and no history of
persistent ketonuria or of ketoacidosis
 BMI ≤27*
 Insulin naive patients: HbA1c ≥6.5% after a minimum of four months’ treatment on oral
hypoglycaemic agents as monotherapy or combination therapy
 Insulin treated patients: HbA1c <9.5% at ongoing insulin therapy
Exclusion and withdrawal criteria
 Type 1 diabetes mellitus or secondary diabetes mellitus
 Weight loss of more than 5.0 kg during the 6 months before enrolment
 HbA1c <6.5% at baseline
 BMI >27 at baseline
 Contraindications for the use of the study drugs (for example, clinical signs of heart,
kidney, or liver failure†)
 Coexisting serious medical conditions†
 HbA1c >10.5% at two separate visits with ≥1 month interval a minimum of four months
after initiation of the randomised study drugs
*The UKProspective Diabetes Study (UKPDS) defined “non-overweight” inpatients with type 2 diabetes asweight within120%
of the ideal body weight accordingto weight for height tables.
13435Hence,the UKPDS investigators did not use BMI as the
measure ofobesity whenallocating patients into treatmentgroups. The BMI corresponding to the 120% ofideal body weight in
the weight for height tables used inthe UKPDS would be about 27.
†Seeweb appendix 1 for details.
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web appendix 1).
The mean of the two measurements a visit of HbA1c
was used for descriptive statistics and as the baseline
estimate; in contrast, both HbA1c measurements from
theendoftreatmentwereevaluatedintheprimaryout-
come analysis. Thus, an analysis of covariance model
was developed for the primary outcome, with patient
astherandomeffect,treatment(metforminplusinsulin
orrepaglinideplusinsulin)asthefixedeffect,andbase-
line levels as the covariate. The secondary outcomes,
havingonly one measurementper visit, were analysed
similarly but without a random effect. Hypoglycaemia
was analysed by a Poisson regression model adjusted
for overdispersion and exposure time. Categorical
data were analysed either as odds ratios by logistic
regression model, with treatment type as the fixed
effect and baseline as the covariate, or as proportions
by Wilcoxon rank sum test. Prespecified analyses on
the basis of patient characteristics, as well as ancillary
analyses of insulin doses and number of injections,
were made by adding fixed effects and interaction
terms to the analysis of covariance model.
Data are given as mean (standard deviation) or as
median or geometric mean (range; or coefficient of
variation) for non-normally distributed variables.
Treatment effects are given as mean (standard error)
or mean (95% confidence intervals). All data are
reported as raw values except for differences between
treatments and changes from baseline (treatment
effects),which are reportedas adjustedvalues.No cor-
rections for multiple testing were performed.
Thestudywasdesignedtohaveastatisticalpowerof
80% to detect a 0.50% absolute difference in HbA1c
concentration, with an estimated standard deviation
of 0.8% at a 5% two sided significance level. Accord-
ingly, 100 enrolled subjects were required to allow for
16 drop outs. The difference in primary outcome con-
sidered to be clinically relevant—that is, the equiva-
lence (non-inferiority) margin—was defined as an
absolute HbA1c difference between treatments of
±0.50%.
3940 This value was chosen to increase the like-
lihood of detecting a potential difference of 0.6% in
HbA1c,asreportedbetweentheconventionalandmet-
formin treated groups in the UKPDS.
1 Statistical ana-
lyses were done with Statistical Analysis System,
version9.1.3(SASInstitute,Cary,NC,USA)orStatis-
tical Package for the Social Sciences, version 14.0 (SP
SS Inc, Chicago, IL, USA).
RESULTS
Patient characteristics
Atotalof102patientswererandomlyallocatedtoeither
study arm (fig 1). Among the 102 randomised patients,
one individual (randomised to insulin plus repaglinide)
who never started the study medication and who
dropped out during the first week after randomisation
was excluded from all statistical analyses. Therefore,
101 patients were included in the intention to treat ana-
lysis, 52 of whom initiated treatment with metformin
plus insulin and 49 who started on repaglinide plus
insulin. Among the 101 patients who were randomly
allocated treatment, four patients (4.0%) dropped out
(fig 1). Thus, 51 patients (98.1%) completed the
12 monthtreatment periodwithmetforminplus insulin,
and 46 patients (93.9%) completed repaglinide plus
insulin. Screen failures or protocol deviations during
therandomisedinterventionswereobservedinafurther
seven patients (see web appendix 1)—these patients
were included in all analyses.
Thosepatientswhowereinvitedbutdeclinedtopar-
ticipate were on average about three years older and
had diabetes for two years longer than patients who
agreed to participate (P=0.001 and P=0.002, respec-
tively). By contrast, sex, body weight, BMI, and
HbA1c concentration did not differ significantly
between these groups. Also, patients who were ran-
domly assigned treatment did not have a significantly
different duration of diabetes from those patients who
were approached but not randomised (including those
who declined invitation), whereas differences in age,
Visit (months from randomisation)
H
a
e
m
o
g
l
o
b
i
n
A
1
c
 
(
%
) HaemoglobinA1c
0
0
5
6
7
8
9
P=0.177
Metformin plus insulin Repaglinide plus insulin
3 6 9 12
T
o
t
a
l
 
d
a
i
l
y
 
i
n
s
u
l
i
n
 
d
o
s
e
 
(
u
n
i
t
s
) Total daily insulin dose
0
10
20
30
40
50
P=0.233
B
o
d
y
 
w
e
i
g
h
t
 
(
k
g
) Body weight
0
65
70
75
80
85
P=0.002
Fig 2 | Metabolic variables during 12 months of treatment with
metformin plus insulin or repaglinide plus insulin. Data
represent the number of patients with available data at each
visit (that is, excluding drop outs), whereas P values represent
tests with last observation carried forward
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those between individuals who declined or agreed to
participate.
All patients were white and aged approximately
60 years (table 1). About two thirds were male, and the
median duration of diabetes was 8-12 years. The mean
BMI was 24-25 and, before enrolment, about 80% of
patients used oral hypoglycaemic agents and about
40% used insulin (about 20% of patients used both).
Mean HbA1c concentration at enrolment was 7.8%.
Regarding diabetes complications, about half of the
participantshad retinopathy,a quarterhadmicroalbu-
minuria or macroalbuminuria, a third had cardio-
vascular disease (macroangiopathy), and most had
neuropathy.Atotalofsevenpatients(7%)hadpositive
glutamic acid decarboxylase 65 antibody titres, with a
further four patients having weak positive titres
(table 1). No patients had a family history of auto-
somally inherited diabetes.
Ofthefourpatientswhodroppedoutofthestudyafter
randomisation,allwereglutamicaciddecarboxylase65
antibodynegativeandhadameanHbA1cconcentration
at baseline of 7.46% and at screening of 8.18%.
Main outcomes
ThemeanHbA1cconcentrationdecreasedbyapproxi-
mately1% duringtheinitial sixmonthsoftreatmentin
both treatment groups and stabilised thereafter. At the
end of treatment, both treatment groups achieved a
mean level of HbA1c below 7.0%, with no significant
difference between treatments (P=0.177; fig 2 and
table 2).
The number of patients who achieved an HbA1c
concentration of less than 6.5% at the end of treatment
was not significantly different between treatment
groups (P=0.169; table 3). The glycaemic response to
treatment did not seem to differ according to previous
insulin treatment or known duration of diabetes. In
those patients who had negative glutamic acid decar-
boxylase 65 antibody status, however, HbA1c concen-
tration was apparently lowered more with insulin plus
metformin than with insulin plus repaglinide (differ-
ence in mean HbA1c −0.27% (−0.55 to 0.00),
P=0.052; P=0.037 for the interaction of treatment by
glutamic acid decarboxylase 65 status).
The change in HbA1c concentration from baseline
seemed to vary according to the number of daily insu-
lin injections at the end of treatment (fig 3). The mean
self monitored plasma glucose concentration
decreased to a similar extent in both treatment groups
(P=0.103;table 2).Attheendoftreatment,theconcen-
trations of self monitored plasma glucose appeared
lower before and after breakfast in the metformin
plus insulin group than in the repaglinide plus insulin
group; however, these differences in self monitored
plasma glucose did not reach statistical significance
(before breakfast −0.54 mmol/l, 95% CI −1.10 to
0.01, P=0.055; 90 minutes after breakfast
−0.98 mmol/l, 95% CI −1.96 to 0.00, P=0.051; fig 4).
There was no significant difference between treat-
ments in the total daily insulin dose at the end of treat-
ment (P=0.233; fig 2 and table 2). The proportion of
patients who received insulin injections once a day,
twiceaday,orthreetimesadayattheendoftreatment
was not significantly different between treatments
(P=0.870). Likewise, there were no significant differ-
ences between treatment arms in the insulin dose at
individual injections during the day (table 3).
Table 1 |Patient characteristics at enrolment (n=101)
Metformin + insulin (n=52) Repaglinide + insulin (n=49)
Gender (n (%))
M e n 3 1( 5 9 . 6 ) 3 1( 6 3 . 3 )
Women 21 (40.4) 18 (36.7)
Age (years)
* 63.0 (7.8) 63.7 (7.9)
Known duration of diabetes (years)
† 8 (1-30) 12 (2-25)
Body weight (kg)
* 72.82 (11.39) 73.84 (10.64)
Height (m)
* 1.72 (0.10) 1.72 (0.08)
BMI
*‡ 24.53 (2.33) 24.88 (2.45)
Waist circumference (cm)
* 92.21 (8.83) 92.39 (8.83)
Hip circumference (cm)
* 96.31 (5.89) 96.96 (5.81)
Waist/hip ratio
* 0.96 (0.07) 0.95 (0.07)
HaemoglobinA1c concentration (%)
* 7.80 (0.97) 7.82 (1.23)
Glutamic acid decarboxylase 65 antibodies
§ §
Positive 5 (9.6) 2 (4.1)
Weak positive 1 (1.9) 3 (6.1)
Negative 45 (86.5) 44 (89.8)
Late diabetes complications (n (%))
Retinopathy
None 28 (53.8) 24 (48.0)
S i m p l e x 2 2( 4 2 . 3 ) 2 2( 4 5 . 8 )
Proliferative 2 (3.8) 3 (6.3)
Macroangiopathy
¶ 19 (36.5) 16 (32.7)
Nephropathy
**
Normoalbuminuria 39 (75.0) 37 (75.5)
Microalbuminuria 11 (21.2) 7 (14.3)
Macroalbuminuria 2 (3.8) 5 (10.2)
Neuropathy
†† 42 (80.8) 43 (87.8)
Pre-study antihyperglycaemic treatment (n (%))
Diet only 1 (1.9) 0 (0)
Oral agents (any use)
‡‡ 45 (86.5) 38 (77.6)
Metformin 33 (63.5) 25 (51.0)
Insulin secretagogues
§§ 38 (73.1) 33 (67.3)
Oral agents only
‡‡ 32 (61.5) 29 (59.2)
Metformin only 2 (3.8) 0 (0)
Insulin secretagogues only
§§ 6 (11.5) 10 (20.4)
Metformin plus an insulin
secretagogue
§§
24 (46.2) 19 (38.8)
Insulin (any use) 19 (36.5) 20 (40.8)
Insulin only 6 (11.5) 11 (22.4)
Insulin plus oral agents
‡‡ 13 (25.0) 9 (18.4)
*Mean (standard deviation).
†Median (range).
‡Mean (standard deviation) BMI at baseline was 24.28 (2.20) in the metformin plus insulin group and 24.49
(2.34) in the repaglinide plus insulin group.
§<5 U/ml=negative; 5-10 U/ml=weak positive; >10 U/ml=positive.
¶Previous cardiovascular disease considered of atherosclerotic origin.
**Normoalbuminuria, microalbuminuria, and macroalbuminuria: 24-hour urinary albumin excretion ≤29 mg, 30-
299 mg, and ≥300 mg, respectively, in two out of three consecutive samples before enrolment.
††Symptomatic peripheral or autonomic neuropathy, or clinical signs of neuropathy.
‡‡Oral agents included metformin, repaglinide, or sulphonylureas.
§§Insulin secretagogues included repaglinide or sulphonylureas.
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increase during the first 6 months but stabilised there-
after (fig 2). The change in body weight at the end of
treatment appeared lower in the metformin plus insu-
lin group than in the repaglinide plus insulin group
(P=0.002; fig 2 and table 2).
Compliance and study drug exposure
The mean compliance of active study drugs was
approximately 96% in both treatment groups.
Approximately 30% of patients in either group
received a reduced study drug dose, resulting in a
meanstudydrugexposureof1771mg/dayformetfor-
min and 5.2 mg/day for repaglinide (table 3).
Adverse events
The number of either mild or nocturnal hypoglycae-
mic episodes, as well as the number of episodes of
major hypoglycaemia, was not significantly different
between treatments (table 4).
Besides the 15 major hypoglycaemic episodes, two
serious adverse events potentially related to the study
medicationwererecordedintherepaglinideplusinsu-
lin group (the drop-out patient with suspected allergic
reaction to insulin and one patient with treatment
emergent diarrhoea requiring hospital admission).
During randomised treatment, a further 19 non-
hypoglycaemia related serious adverse events consid-
ered unrelated to the study medication were recorded
(metformin plus insulin: eight events; repaglinide plus
insulin: 11 events; see web appendix 2). No cases of
lactic acidosis occurred.
DISCUSSION
Principal findings
Inthisrandomised,doubleblindstudy,101non-obese
patientswithtype2diabeteswhohadglycaemicfailure
after four months on oral hypoglycaemic agents com-
bination therapy received metformin plus biphasic
insulin aspart 70/30 or repaglinide plus biphasic insu-
lin aspart 70/30 for 12 months. Both treatment groups
achieved similar and near optimal glycaemic regula-
tion with similar doses of insulin, which suggests that
metformin and repaglinide are equally effective dia-
betes treatments in such patients. Weight gain,
Table 2 |Metabolism related variables before and at the end of treatment
Before treatment (mean
(standard deviation or range))
End of treatment (mean
(standard deviation or range))
Change from before treatment (mean (standard error,
coefficient of variation, or 95% confidence interval))
Metformin +
insulin (n=52)
Repaglinide +
insulin (n=49)
Metformin +
insulin(n=51)
Repaglinide +
insulin (n=47)
ΔMetformin+
insulin(n=51)
ΔRepaglinide +
insulin (n=47)
ΔMetformin + insulin versus
ΔRepaglinide + insulin P value
Glycaemic control (primary outcome)
HaemoglobinA1c
concentration (%)
8.15 (1.32) 8.07 (1.49) 6.72 (0.66) 6.90 (0.68) −1.42 (0.09) −1.23 (0.10) −0.18 (−0.45 to 0.08) 0.177
Glycaemic control (secondary outcomes)
Mean plasma glucose
(mmol/l)
*
10.66 (2.76) 10.55 (3.20) 7.63 (1.28) 8.02 (0.98) −3.12 (0.17) −2.72 (0.17) −0.40 (−0.89 to 0.08) 0.103
Total daily insulin dose
(units)
†
0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 32.96(9to84) 28.25 (6 to 108) 32.96 (48.1) 28.25 (74.6) 1.17 (0.90 to 1.51) 0.233
Anthropometric variables
Body weight (kg) 72.07 (10.98) 72.67 (10.16) 74.45 (12.27) 77.66 (12.11) 2.22 (0.54) 4.73 (0.57) −2.51 (−4.07 to −0.95) 0.002
Data for before treatment (baseline; 0 months) and end of treatment (12 months with last observation carried forward) are presented as raw absolute (unadjusted) values and are
summarised as mean (standard deviation), whereas data for the changes from baseline are baseline adjusted changes (including last observation carried forward) and are summarised as
mean (standard error or 95% confidence interval, except for insulin dose
†). The last observation was carried forward for HbA1c and insulin dose, but not for mean plasma glucose or body
weight. The number of patients in each column represents the maximum number of patients with available measurements either at baseline or in the intention to treat analysis at the end of
treatment.
*Mean of seven point self monitored plasma glucose.
†Baseline and end of treatment data are presented as geometric mean (range), whereas changes from baseline are presented as either geometric mean (coefficient of variation) or the ratio
between treatment effects (95% confidence interval).
Baseline HbA1c
One injection
(n=17)
7.2% (0.5)
Two injections
(n=42)
8.0% (1.3)
Three injections
(n=42)
8.7% (1.5)
∆
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%
)
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Fig 3 | Change in haemoglobinA1c (HbA1c) concentration from
baseline at the end of treatment. Data represent subgroups of
patients according to the number of daily insulin injections at
the end of treatment. The mean (standard deviation) baseline
HbA1c concentration is indicated for each column. Changes
from baseline are presented as mean (±2 standard errors of
the mean). All estimates were produced by an analysis of
variance model without adjustment for baseline HbA1c
concentration. In a similar model with adjustment for baseline
HbA1c, changes in HbA1c from baseline were statistically
significant in all subgroups (data not shown). Within each
subgroup, the difference between metformin plus insulin and
repaglinide plus insulin was not statistically significant in
either of these models (data not shown). The number of
patients shown in the figure represents the intention to treat
population at baseline. Efficacy data are presented with last
observation carried forward (one injection: n=14; two
injections: n=42; three injections n=42)
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insulin aspart 70/30 than with repaglinide plus bipha-
sic insulin aspart 70/30.
Theincidenceofmildsymptomaticandmajorhypo-
glycaemiawasnotsignificantlydifferentbetweentreat-
ments. The rate of major hypoglycaemia was 0.1-0.2
per year, which corresponds to one such episode
every five to ten years per patient. The number of
non-hypoglycaemia related serious adverse events
was low.
We used near maximal daily doses of metformin
(2000 mg) and repaglinide (6 mg) and observed a ten-
dency towards lower pre-breakfast and post-breakfast
levels of self monitored plasma glucose with insulin
plus metformin (p=0.055 and p=0.051, respectively;
fig 4). Hence, we cannot exclude the possibility that
in our population of non-obese patients with type 2
diabetes, higher doses of metformin and repaglinide
would have resulted in notable glycaemic differences
between treatment groups.
In contrast to present consensus statements recom-
mending that insulin secretagogues are stopped after
initiation of insulin therapy,
7 our data suggest a clini-
cally relevant effect of insulin and insulin secretago-
gues in combination, even in patients with long
standing diabetes in whom beta cell failure otherwise
could be anticipated (that is, in the present study
patients had preserved beta cell function despite
approximately 10 years of diabetes). Patients in our
study achieved good glycaemic control using a single
oral hypoglycaemic agent in combination with insulin
therapy. Such therapy could thus be more convenient
thantwoormoreoralhypoglycaemicagentsincombi-
nation with insulin therapy. This suggestion is sup-
ported to some degree by the observed low drop out
rate and satisfactory compliance.
Strengths and limitations of study
The initial sample frame of 459 eligible patients is
somewhatsmall;however,weusedtargetedelectronic
searchestoreachthedesirednumberofparticipants,so
approaching all patients at the study site (about 5500
patients) was not needed. As expected, approached
patients who declined were slightly older than those
who accepted, but HbA1c concentration and BMI
(that is, the main phenotypic characteristics of the
population of interest) were not significantly different
between these groups. Hence, we do not believe the
number of eligible patients or the recruitment process
to have confounded the conclusions.
Treatment responses did not seem to be heteroge-
neous according to baseline patient characteristics
such as diabetes duration or previous insulin use, but
may have been affected by the presence of autoim-
mune disease as determined by the presence of gluta-
mic acid decarboxylase 65 antibodies. Only 7% of
participantshadsignsofautoimmunedisease.Itispos-
siblethatthosepatientswithoutsignsofautoimmunity
might have had a better glucose lowering response to
insulin and metformin than to insulin plus an insulin
secretagogue. More precisely, the effect of metformin
wassignificantlydifferenttothatofrepaglinideaccord-
ing to glutamic acid decarboxylase 65 status (inter-
action: P=0.037) and, in those patients without signs
of autoimmunity, the lower 95% confidence interval
limit of −0.55% in difference in HbA1c concentration
between treatments exceeded the predefined ±0.50%
equivalence margin. Importantly, although analyses
Table 3 |Other assessments at the end of treatment
Metformin +
insulin (n=52)
Repaglinide +
insulin (n=49) Pvalue
Number of subjects with haemoglobinA1c concentration
<6.5% (n (%))
22 (42.3) 14 (28.6) 0.169
Frequency of insulin injections (n (%)) 0.870
Once a day 7 (13) 7 (14)
Twice a day 23 (44) 19 (39)
Three times a day 21 (40) 21 (43)
Insulin dose (units; geometric mean (coefficient of variation)) 0.253
Breakfast
* 13.1 (52.8) 10.5 (77.4) 0.132
Lunch
* 6.3 (64.1) 6.4 (74.6) 0.971
Dinner
* 18.6 (51.8) 16.7 (75.3) 0.422
Compliance
Number of patients with reduced active dose during follow-
up
† (n (%))
18 (34.6) 15 (30.6) —
‡
Percentage compliance (mean (SD))
§
Active tablets 96.8 (6.1) 96.1 (10.6) —
‡
Placebo metformin tablets — 96.8 (4.9) —
Placebo repaglinide tablets 94.2 (8.7) ——
Study drug exposure (mg/day; mean (SD))
§ 1771 (441) 5.2 (1.1) —
‡
*The insulin doses at each injection are presented as geometric means.
†Reduced study drug doses were considered to be any study drug dose less than the maximum intended doses
(that is, less than metformin/placebo 2000 mg daily and repaglinide/placebo 6 mg daily, respectively) of any
duration and at any time after initiation of randomised treatments.
‡Not compared statistically.
§Data refer to those patients with available data (metformin plus insulin: n=52; repaglinide plus insulin: n=48).
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Fig 4 | Seven point self monitored plasma glucose
measurements at baseline and at the end of treatment
(12 months). Data are presented as mean (standard error of
the mean)
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these data are only hypothesis generating and should
beaddressedmoreappropriatelyinfuturetrials.Mean
BMIamongparticipantswasslightlybelow25atenrol-
ment, concordant with the notion that at least 20% of
white patients with type 2 diabetes have a BMI of less
than 25 and 35% have a BMI of less than 27.
41-43 Thus,
our study population represented white patients with
type 2 diabetes having a non-obese phenotype.
Some drug intolerance with respect to gastro-
intestinalsideeffectscouldbeanticipatedinmetformin
naive patients (who we expected to be more frequent
among non-obese patients with type 2 diabetes).
Hence, we used a run-in period to establish study
drug tolerance (to potentially minimise the drop-out
rate), as well as failure on oral hypoglycaemic agents
combination therapy. Moreover, by ensuring similar
glucoseloweringtreatmentsforallpatientsatbaseline,
the run-in period served to minimise any confounding
effect of chance differences between groups in pre-
vious glucose lowering therapies.
We used a treat to target regimen, including patient
self titration of insulin dose and increasingthe number
of injections. Hence, an apparently greater reduction
inHbA1cconcentrationwasexpectedasthenumberof
injections increased. In the present study, self moni-
tored plasma glucose results agreed with HbA1c mea-
surements, and we did not observe differences in
insulin doses between treatment groups. The latter
supports the notion that observed differences between
treatment groups, such as weight gain, resulted from
differences between metformin and repaglinide
actions(ratherthanfrompossibledifferencesininsulin
doses)—the key question that we aimed to address.
We did not adjust for multiple testing. Hence, we
emphasise that conclusions can only be drawn from
theresultsfortheprimaryoutcome(HbA1cconcentra-
tion)—other outcomes are hypothesis generating. We
believe multiple testing should be addressed by
replicate studies rather than by, for example, post hoc
modifications of P values.
44
Body weight was a secondary outcome; thus, our
data on this variable must be interpreted cautiously.
Nonetheless, BMI, as an adiposity measure, was an
inclusion criterion and a stratifying variable. Hence,
chance findings were probably less likely to occur for
body weight than for other secondary outcomes.
Comparison with other studies
Most studies investigating combination therapy of
insulin plus oral hypoglycaemic agents have been of
short duration—six monthsor less,
45-47 and only rarely
up to one year.
623 Also, most studies failed to reach
optimal or near optimal glycaemic regulation.
62345-47
In the UKPDS, patients stopped taking oral hypogly-
caemic agents when insulin therapy was initiated.
35
Hence, besides the present study, we are unaware of
other such comparative studies in non-obese patients
with type 2 diabetes.
In obese patients with type 2 diabetes, however,
combination therapy of insulin plus metformin seems
tobesuperiortoinsulinplusaninsulinsecretagoguein
reducing HbA1c concentration, body weight, or
hypoglycaemia.
64548 Also, metformin plus inter-
mediate acting insulin produced lower levels of
HbA1c than repaglinide plus intermediate acting insu-
lin in obese patients with type 2 diabetes, as well as
lower fasting and postprandial plasma glucose levels
despite similar insulin doses.
45 The apparently lesser
weightgainofabout2.5kgwithmetforminplusbipha-
sic insulin aspart 70/30 compared with repaglinide
plus biphasic insulin aspart 70/30 in our study agrees
with findings in obese patients with type 2 diabetes.
645
We used biphasic insulin aspart 70/30 instead of the
otherwisewidelyusedbasalinsulinregimen.Recently,
results from clinical practice, clinical trials and a
meta-analysis demonstrated favourable glycaemic
potentials, such as lower HbA1c concentration, with
Table 4 |Hypoglycaemic episodes during follow-up after randomisation in the intention to treat population
Metformin + insulin (n=52) Repaglinide + insulin (n=49)
Metformin + insulin versus
repaglinide + insulin
Number of
patients(%)
Number of
episodes
Rate per patient
yearsofexposure
Number of
patients(%)
Number of
hypoglycaemic
episodes
Rate per patient
yearsofexposure
Relative risk (95%
confidence interval) P value
All symptomatic episodes
* 51 (98.08) 1238 23.2 47 (95.92) 1418 29.9 0.77 (0.53 to 1.14) 0.198
Nocturnal episodes
†‡ 32 (61.54) 211 3.9 30 (61.22) 212 4.5 0.88 (0.46 to 1.69) 0.708
All major episodes
¶ 4 (7.69) 5 0.1 8 (16.33) 10 0.2 0.44 (0.13 to 1.47) 0.185
All minor episodes
§ 50 (96.15) 1233 23.1 47 (95.92) 1408 29.7 0.78 (0.53 to 1.15) 0.206
Plasmaglucose≤3.5mmol/l 41 (78.85) 475 8.9 38 (77.55) 417 8.8 1.01 (0.62 to 1.64) 0.965
Plasma glucose >3.5 mmol/l
or plasma glucose not
available
‡
46 (88.46) 758 14.2 47 (95.92) 991 20.9 0.68 (0.41 to 1.13) 0.135
*”All symptomatic episodes” is the sum of all major and all minor episodes.
†Nocturnal hypoglycaemic episodes are symptomatic episodes occurring during night time as defined by the patient or between 2300 and 0700.
‡In some patients, a number of events occurred that were recorded as “not quantifiable”—that is, events were reported to have occurred, but the number of these was either not reported or
unknown. These events were categorised among “Nocturnal episodes” and, if events were not nocturnal, as “plasma glucose not available”. Such events was recorded (Nocturnal episodes/
plasma glucose not available) 6/7 times in 5/7 patients in the metformin plus insulin group and 6/5 times in 4/5 patients in the repaglinide plus insulin group. These events were included
in the number of patients reporting events, but not in the number of events.
§Minor hypoglycaemic episodes are symptomatic episodes not recorded as major (nocturnal episodes are included).
¶Major hypoglycaemic episodes are episodes where the patient was not able to treat himself or herself, or unconsciousness induced by hypoglycaemia (nocturnal episodes are included).
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22232849 Thus, given these considera-
tions and those as outlined with respect to the non-
obese phenotype, our present findings can probably
be generalised to a wider population.
The Bypass Angioplasty Revascularization Investi-
gation 2 Diabetes trial in mainly obese patients with
type 2 diabetes and cardiovascular disease did not
find significant differences between insulin sensitising
and insulin providing treatment regimens on
cardiovascular outcomes or mortality.
50 Major hypo-
glycaemia, however, was more frequent with insulin
provision than insulin sensitisation. Accordingly, in
thepresentstudymajorhypoglycaemiaappearednom-
inally more frequent with repaglinide plus biphasic
insulinaspart70/30thanwithmetforminplusbiphasic
insulinaspart70/30(16%v8%ofpatients,respectively;
table 4). Our study was not statistically powered to
show differences in major hypoglycaemia or “hypo-
glycaemic safety.” Nevertheless, a clinically relevant
differenceinmajorhypoglycaemiacouldexist,despite
being statistically insignificant in this study.
The observed risk of major hypoglycaemia with
insulin plus repaglinide was very similar to that in the
intensive glucose control group in the Action to Con-
trol Cardiovascular Risk in Diabetes trial.
51 Increased
mortality with intensive compared with conventional
glucose control was also observed in that trial; how-
ever, the cause of the increased mortality remains to
be identified. Thus, in our opinion, changing the
glucose lowering treatment should be considered
in patients experiencing frequent or major hypo-
glycaemiceventsontreatmentwithinsulinandinsulin
secretagogues.
We aimed to lower HbA1c concentration to below
6.5%. The choice of target is supported by clinical
event studies in which an HbA1c target of less than
6.0% was associated with increased mortality,
51
whereasanHbA1ctargetof6.5%orlesswasassociated
with a reduced risk of microvascular complications
without an adverse increase in the risk of cardio-
vascular disease or mortality.
52
We did not include an insulin only group (that is, an
insulinplusplacebooralhypoglycaemicagentsgroup)
primarily owing to the well established superiority of
insulinplusoralhypoglycaemicagentscomparedwith
an insulin only regimen; for example, for glycaemic
regulation in obese patients with type 2
diabetes.
364653-55 Likewise, we did not investigate insu-
linontopofcombinationtherapywithmetforminplus
repaglinide. The 96% increase in mortality among
patients on combination treatment with metformin or
insulinsecretagoguesobservedintheUKPDSisworri-
some
1—especially when combination therapy is used
for long term treatment (for example, with insulin
treatment). Notably, combination therapy with two
or more oral hypoglycaemic agents in patients with
type 2 diabetes has recently been subject to further
safety concerns.
51
The 1-2 percentage points lowering of HbA1c con-
centration in our study is promising. In the UKPDS, a
0.9 percentage points difference in HbA1c concentra-
tion was associated with improved clinical
outcomes.
235We cannot draw any conclusions about
long term clinical outcomes from the present study in
about100non-obesepatientswithtype2diabetestrea-
tedfor12months.However,providedthatloweringof
HbA1c concentration has in itself beneficial microvas-
cularandmacrovasculareffectswithoutadverseeffects
on mortality (as suggested by, for example, the
UKPDS as well as by recent meta-analyses),
2355657
our results of near optimal glycaemic regulation
withinsulinplusmetforminorplusrepaglinidesuggest
thesetherapiesmightbeusedfavourablyin non-obese
patients with type 2 diabetes.
Conclusions
At present, there is an almost complete lack of evi-
dence to guide treatment choices, including the use of
metformin,fornon-obesepatientswithtype2diabetes.
The present study adds to the evidence base for treat-
ment of hyperglycaemia in patients with type 2 dia-
betes. In non-obese patients with long standing type 2
diabetesandglycaemicfailureafterfourmonthsoforal
hypoglycaemic agents combination therapy, treat-
ment with metformin plus biphasic insulin aspart 70/
30 or repaglinide plus biphasic insulin aspart 70/30
resultedin nearoptimaland equivalent glycaemic reg-
ulation after one year. The difference in the incidence
of major hypoglycaemia between the two treatment
groups was not significant, although it seemed more
frequent with repaglinide plus biphasic insulin aspart
70/30 treatment. Metformin plus biphasic insulin
aspart 70/30 seemed to be associated with less weight
gain, despite the fact that the insulin dose used was the
same in the two treatment arms.
This study suggests that in non-obese patients with
type 2 diabetes, the use of metformin or, in those
patientswhoremainfreeofsignificanthypoglycaemia,
aninsulinsecretagogueasanadjuncttherapytoinsulin
might have beneficial effects on glycaemic control.
Future studies should further address clinical events
during interventions.
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